Search

Your search keyword '"Woodman, Richard C."' showing total 3 results
Start Over Author "Woodman, Richard C." Journal leukemia research
3 results on '"Woodman, Richard C."'

3. Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

Author

O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, and Conneally E

Subjects
Adult, Aged, Drug Administration Schedule, Drug Monitoring instrumentation, Drug Monitoring statistics & numerical data, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Likelihood Functions, Male, Middle Aged, Neoplasm, Residual, Prospective Studies, Real-Time Polymerase Chain Reaction, Treatment Outcome, Antineoplastic Agents therapeutic use, Drug Monitoring methods, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pyrimidines therapeutic use
Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p = 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting., (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results